Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 55Carcinoma, Non-Small-Cell Lung 33Stomach Neoplasms 28Colorectal Neoplasms 26Small Cell Lung Carcinoma 19Lung Neoplasms 18Rectal Neoplasms 16Pancreatic Neoplasms 14Neoplasms 14Neoplasm Metastasis 14Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Carcinoma, Hepatocellular 11Recurrence 10Leukemia, Myeloid, Acute 10Melanoma 9Esophageal Squamous Cell Carcinoma 8Colonic Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Head and Neck Neoplasms 7Hodgkin Disease 6Cholangiocarcinoma 6Adenocarcinoma of Lung 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms, Germ Cell and Embryonal 5

Interventions

pyrotinib 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × HER2 Positive Metastatic Breast Cancer × Clear all
NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Henan Cancer Hospital

Phase 2 Unknown
46 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡